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Malaria infection is often complicated by malaria-asso-
ciated acute respiratory distress syndrome (MA-ARDS),
characterized by pulmonary edema and hemorrhages.
No efficient treatments are available for MA-ARDS and
its pathogenesis remains poorly understood. To develop
a new animal model for MA-ARDS, mice were infected
with Plasmodium berghei NK65, and the development of
MA-ARDS was characterized by increased lung weight,
edema, leukocyte infiltration and hemorrhages (Figure 1).
The pulmonary expression of several cytokines and che-
mokines was increased to a higher level than in mice
infected with P. chabaudi AS, which does not cause MA-
ARDS. By depletion experiments, CD8+ T lymphocytes
were shown to be pathogenic. High doses of dexametha-
sone blocked MA-ARDS, even when administered after
appearance of the complication, and reduced pulmonary
leukocyte accumulation.
We developed a novel model of MA-ARDS with many
similarities to human MA-ARDS and without cerebral
complications. This contrasts with the more classical
model with P. berghei ANKA, characterized by fulminant
cerebral malaria. Hence, infection with P. berghei NK65
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Figure 1 Histopathology of P. berghei NK65-induced MA-ARDS. Frozen sections of lungs of mice infected for 10 days with P. berghei NK65 or
control mice were stained with H&E.The black bar corresponds with 100 μm.
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generates a broader time window to study the pathogen-
esis and to evaluate candidate treatments. The finding
that high doses of dexamethasone cured MA-ARDS sug-
gests that it might be more effective against MA-ARDS
than it was in the clinical trials for cerebral malaria.
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